| Treatment vs. Control | N of studies | Treatment | Control | I^2 | | Relative Risk (95% CI) |
|--------------------------|--------------|-----------|----------|-----|---------------------------------------|------------------------|
| Follow-up | | events/n | events/n | | | |
| T-2b uni vs. T-2b bi | | , , | | | | |
| 3 years | 1 | 19 / 72 | 8 / 31 | na | · · · · · · · · · · · · · · · · · · · | 1.02 (0.50 – 2.08) |
| 4 years | 1 | 31 / 72 | 11 / 31 | na | | 1.21 (0.70 – 2.09) |
| 5 years | 1 | 34 / 72 | 16 / 31 | na | | 0.91 (0.60 – 1.39) |
| 6 years | 1 | 34 / 72 | 16 / 31 | na | | 0.91 (0.60 – 1.39) |
| T-2a left vs. T-2a right | | | | | | |
| 3 years | 1 | 4 / 15 | 3 / 16 | na | - | 1.42 (0.38 – 5.33) |
| 4 years | 1 | 6 / 15 | 9 / 16 | na | | 0.71 (0.33 – 1.51) |
| T-2c vs. T-2a | | | | | | |
| 3 years | 1 | 28 / 74 | 15 / 79 | na | · · · · · · · · · · · · · · · · · · · | 1.99 (1.16 – 3.42) |
| 5 years | 1 | 22 / 34 | 20 / 34 | na | | 1.10 (0.76 – 1.60) |
| | | | | (| 0.25 0.50 1.0 2.0 4.0 | 8.0 |